Loading
Blood tests can already detect tumour DNA. Reporting which sub-populations of the tumour are growing or shrinking, cycle by cycle, would turn the test into an evolution monitor.
Phylogenetic ctDNA analysis, as developed in TRACERx, assigns plasma variants to tumour subclones and tracks their relative abundance. The proposal is a standardised clinical report in which each ctDNA draw lists clone fractions, emergent clones, and clone-specific drug sensitivities, rather than a flat list of variants and allele frequencies.
Shares Tumour heterogeneity and clonal evolution, Osimertinib, Acquired resistance to every therapy, Liquid biopsy (ctDNA).
Shares Molecular-progression switching beyond ESR1, Osimertinib, Acquired resistance to every therapy, Liquid biopsy (ctDNA).
Shares Variant allele frequency (VAF), Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Liquid biopsy (ctDNA).
Shares Tumour heterogeneity and clonal evolution, Osimertinib, Acquired resistance to every therapy, Liquid biopsy (ctDNA).
Shares Tumour heterogeneity and clonal evolution, Osimertinib, Acquired resistance to every therapy, Circulating tumour DNA (ctDNA).
Shares Variant allele frequency (VAF), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Molecular-progression switching beyond ESR1, Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Liquid biopsy (ctDNA), Non-small-cell lung cancer.